The Food and Drug Administration (FDA) has issued a discontinuation notice for Bydureon® (exenatide extended-release; AstraZeneca) for injectable suspension Single Dose Trays. 

The 2mg Single Dose Tray presentation will be permanently discontinued on September 30, 2018. There are two other delivery options for Bydureon: the Dual Chamber Pen and the BCise autoinjectors.

Bydureon, a glucagon-like peptide-1 (GLP-1) receptor agonist, is currently approved as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes. It works by enhancing glucose-dependent insulin secretion by the pancreatic beta-cell, suppressing inappropriately elevated glucagon secretion, and slowing gastric emptying.

The Dual Chamber Pen is supplied in cartons containing 4 single-dose pens; the BCise is available as cartons containing 4 single-dose autoinjectors.

For more information call (800) 236-9933 or visit FDA.gov.

Related Articles

This article originally appeared on MPR